Brought to you by 
Forty Seven raises first half of $75mm Series A round; closes round
30 Mar 2021
Executive Summary
Stanford University spin-out Forty Seven Inc. raised the first half of a committed $75mm Series A round to fund its development work in immuno-oncology. Co-leads Lightspeed Venture Partners and Sutter Hill Ventures were joined by Clarus Ventures and GV (formerly Google Ventures) in the financing.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forty Seven raises first half of $75mm Series A round; closes round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice